Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.  Over 60% of neurologists in ITG's study cited safety concerns and monitoring as limiting their use of the drug, but most indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.  Early switching data from ITG's proprietary panel of neurologists indicates that BIIB's Avonex may be the biggest loser of all, as nearly one-third of switches to Gilenya thus far have been from Avonex.

The study titled Event Pulse: Launch of Gilenya shows that Gilenya has been detailed heavily to neurologists since its launch.  Neurologists in the study reported more frequent details on Gilenya in November than any of the other MS therapies.  Study findings reveal that Novartis reps seem to be promoting the drug's unique oral formulation and its efficacy compared to market leaders, especially Biogen Idec's Avonex. Still, results from the study show that Novartis has not been able to completely allay neurologists' concerns about Gilenya's safety. Until resolved, Gilenya will likely be prescribed primarily for patients who have discontinued or have had an inadequate response to other MS therapie
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Cambrex Corporation (NYSE: CBM ) reports results for the ... , Sales increased 18% compared to the first ... driven by Innovator products and Controlled Substances. , EBITDA ... quarter of 2014. , GAAP Diluted EPS from continuing ... year and Adjusted Diluted EPS was $0.29 compared to $0.07 ...
(Date:4/30/2015)... April 30, 2015 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the fourth ... Fourth quarter and fiscal 2015 overview: , ... fourth quarter, up 33% over last year,s comparable quarter, ... , Diluted EPS of $0.50 for the fourth ...
(Date:4/30/2015)... , April 30, 2015  IRIDEX Corporation (NASDAQ: ... its first quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, May 7, ... and other business developments. Interested parties may ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... Calif., Sept. 1, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... that management will present a company overview at Stifel Nicolaus, ... p.m. ET at the Four Seasons Hotel in Boston. ... available on the "Investors & Media" section of the Company,s ...
... Sept. 1, 2011 People seeking support ... prepare to be disappointed – and to make a ... cardiologist, Dr. Carl Lavie, medical director of Cardiac Rehabilitation ... Orleans, LA, "flush-free" niacin may not cause flushing, but ...
Cached Medicine Technology:Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 2Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 3
(Date:5/3/2015)... ST. LOUIS, Missouri (PRWEB) May 03, 2015 ... in international business that will directly impact your ... (EMIB), is designed for dynamic leaders in multinational ... a multinational company. In a changing global landscape, ... business negotiations and relationships. The EMIB program develops ...
(Date:5/3/2015)... SpineFrontier, a Less Exposure Surgery (LES) technology ... and market their new sacroiliac joint fusion screw, the ... settings and is compatible with both lateral and alternate ... extensively researched and refined by SpineFrontier, the first company ... in conjunction with a sacroiliac joint fusion system like ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and Windows. Joe ... app review and shared with viewers how this app allows ... , In this material world, almost everything is about money. ... is why those things should be prioritized above others. And ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... children in Ecuador whose mothers were exposed to pesticides while ... copy geometric figures as compared to a control group. This ... issue of Paediatrics. ,Philippe Grandjean, ... led a team of researchers and analyzed data on 72 ...
... who have a slower rate of caffeine metabolism as ... increased risk //for development of non-fatal heart attack, following ... most important source of caffeine and deserves the credit ... worldwide. Several studies have highlighted the possibility of cardiovascular ...
... South Dakota signed a law banning abortions, which may be ... which may trigger national debate. // ,The law ... decision, known as Roe vs. Wade, that made it legal ... ,Governor Mike Rounds, a member of President George W. ...
... The cost of treatment at the community-built Riverina Cancer Care ... around reduction in prices, which will bring about the much ... happened following fears expressed by the cancer support groups that ... Hull, who is the Federal Member for Riverina, is hopeful ...
... on the plane to the gulf, not so much for greener ... Gulf. // The demand for rabbit meat has increased following the ... desert, for what was a dry gulf palate sans the chicken. ... meat and this has led to several enquiries flooding the State ...
... birth defects is improved by incorporation of folic acid in ... been known that folic acid supplementation during pregnancy can reduce ... anencephaly etc. ,The researchers analyzed the effect of ... born with spina bifida between the year 1998 and 2001. ...
Cached Medicine News:
... Give patients the best potential for quality ... IQ IOL compensates for spherical aberration by ... periphery. This is accomplished without increasing edge ... to create a design that provides improved ...
... Advanced Optics Aspheric Lens System can ... IOL all your cataract patients will ... quality and contrast sensitivity. With a ... should consistently deliver superior optical performance ...
... Defibrillator was designed to be as easy ... and shares many of its features, including ... Philips HeartStart Home Defibrillator is an automated ... home use by untrained users. Although small ...
... 64-channel configuration breaks through previous boundaries ... thin-slice coverage to improve diagnostic confidence, ... 40mm of thin-slice coverage, the 64-channel ... for unprecedented coronary artery evaluation. The ...
Medicine Products: